Metagenomi Therapeutics Statistics
Total Valuation
MGX has a market cap or net worth of $54.93 million. The enterprise value is -$65.22 million.
Important Dates
The last earnings date was Thursday, March 5, 2026, after market close.
| Earnings Date | Mar 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
MGX has 37.62 million shares outstanding. The number of shares has increased by 12.79% in one year.
| Current Share Class | 37.62M |
| Shares Outstanding | 37.62M |
| Shares Change (YoY) | +12.79% |
| Shares Change (QoQ) | +0.34% |
| Owned by Insiders (%) | 10.48% |
| Owned by Institutions (%) | 20.98% |
| Float | 27.33M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.18 |
| Forward PS | 2.52 |
| PB Ratio | 0.35 |
| P/TBV Ratio | 0.35 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.22, with a Debt / Equity ratio of 0.26.
| Current Ratio | 7.22 |
| Quick Ratio | 7.08 |
| Debt / Equity | 0.26 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -44.67% and return on invested capital (ROIC) is -25.01%.
| Return on Equity (ROE) | -44.67% |
| Return on Assets (ROA) | -21.99% |
| Return on Invested Capital (ROIC) | -25.01% |
| Return on Capital Employed (ROCE) | -48.45% |
| Weighted Average Cost of Capital (WACC) | 3.93% |
| Revenue Per Employee | $203,306 |
| Profits Per Employee | -$708,613 |
| Employee Count | 124 |
| Asset Turnover | 0.09 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -58,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -28.78% in the last 52 weeks. The beta is 0.47, so MGX's price volatility has been lower than the market average.
| Beta (5Y) | 0.47 |
| 52-Week Price Change | -28.78% |
| 50-Day Moving Average | 1.59 |
| 200-Day Moving Average | 1.91 |
| Relative Strength Index (RSI) | 44.38 |
| Average Volume (20 Days) | 249,764 |
Short Selling Information
The latest short interest is 1.93 million, so 5.13% of the outstanding shares have been sold short.
| Short Interest | 1.93M |
| Short Previous Month | 1.98M |
| Short % of Shares Out | 5.13% |
| Short % of Float | 7.07% |
| Short Ratio (days to cover) | 8.12 |
Income Statement
In the last 12 months, MGX had revenue of $25.21 million and -$87.87 million in losses. Loss per share was -$2.36.
| Revenue | 25.21M |
| Gross Profit | -69.22M |
| Operating Income | -96.01M |
| Pretax Income | -87.93M |
| Net Income | -87.87M |
| EBITDA | -90.70M |
| EBIT | -96.01M |
| Loss Per Share | -$2.36 |
Full Income StatementBalance Sheet
The company has $160.80 million in cash and $40.66 million in debt, with a net cash position of $120.14 million or $3.19 per share.
| Cash & Cash Equivalents | 160.80M |
| Total Debt | 40.66M |
| Net Cash | 120.14M |
| Net Cash Per Share | $3.19 |
| Equity (Book Value) | 158.60M |
| Book Value Per Share | 4.22 |
| Working Capital | 142.61M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$88.89 million and capital expenditures -$574,000, giving a free cash flow of -$89.47 million.
| Operating Cash Flow | -88.89M |
| Capital Expenditures | -574,000 |
| Free Cash Flow | -89.47M |
| FCF Per Share | -$2.38 |
Full Cash Flow StatementMargins
| Gross Margin | -274.59% |
| Operating Margin | -380.85% |
| Pretax Margin | -348.77% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
MGX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -12.79% |
| Shareholder Yield | -12.79% |
| Earnings Yield | -159.98% |
| FCF Yield | -162.88% |
Analyst Forecast
The average price target for MGX is $9.25, which is 533.56% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $9.25 |
| Price Target Difference | 533.56% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | -2.05% |
| EPS Growth Forecast (5Y) | -10.12% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
MGX has an Altman Z-Score of -1.78 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.78 |
| Piotroski F-Score | 1 |
